IPO Ideas

Go to page

Browse IPO Ideas — market data, blogs, legal pages, and more.

Anlon Healthcare Limited IPO logo

Anlon Healthcare Limited IPO

BBMainboardBSE, NSEListed
Listed at
92
+1.10%

Anlon Healthcare Limited IPO is a Mainboard book building IPO. Price band is ₹91 per share. Minimum investment is ₹14,924. Lot size is 164 shares. Open from 26 Aug 2025 to 29 Aug 2025. Allotment on 1 Sept 2025. Listing on 3 Sept 2025 at BSE, NSE. Managed by Interactive Financial Services Ltd. Registrar: Kfin Technologies Limited. Key details for GMP, subscription, price, allotment, and listing in one place.

Official documents: RHP and DRHP.

Anlon Healthcare Limited IPO overview

Anlon Healthcare Limited IPO Key figures

Price band, lot, minimum application, and issue window at a glance.

Price band
₹91
Lot size
164 shares / lot
Min investment
₹14,924
Issue open – close
26 Aug 2025 → 29 Aug 2025

Anlon Healthcare Limited IPO important dates

Issue Opens
26 Aug 2025
Issue Closes
29 Aug 2025
Allotment
1 Sept 2025
Listing
3 Sept 2025

Anlon Healthcare Limited IPO lot size

CategoryLotsSharesAmount
Retail (Min)116414,924
Retail (Max)132,1321,94,012
S-HNI (Min)142,2962,08,936
S-HNI (UPI)335,4124,92,492
S-HNI (Max)6710,9889,99,908
B-HNI (Min)6811,15210,14,832

Quick Profit Calculator for Anlon Healthcare Limited IPO

Pre-filled: Issue Price = ₹91, Lot Size = 164 shares, Listing Price = ₹92

CategoryLotsInvestmentAt listingProfit
Retail (Min)114,92492+₹164
Retail (Max)131,94,01292+₹2,132
S-HNI (Min)142,08,93692+₹2,296
S-HNI (UPI)334,92,49292+₹5,412
S-HNI (Max)679,99,90892+₹10,988
B-HNI (Min)6810,14,83292+₹11,152

Profit based on the official listing price for each investor category.

About Anlon Healthcare Limited IPO

From the company / RHP narrative.

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products). The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP. In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs. The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards. The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage. Products: Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs. Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products. Competitive Strengths: Strong product portfolio and scalable business. Strong Promoters and Experienced Management Team. High entry and exit barriers due to long customer approval cycles and strict product standards. In-house Testing, Quality Control and Quality Assurance for quality control. Focus on Quality, Environment, Health and Safety.

Anlon Healthcare Limited IPO Issue Objective

How the issuer plans to use IPO proceeds.

Funding capital expenditure requirements for Proposed Expansion Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company Funding the working capital requirements of the Company General corporate purposes

Anlon Healthcare Limited IPO FAQs

A quick overview of key terms, dates, and how to track this IPO.

What is Anlon Healthcare Limited IPO?
Anlon Healthcare Limited IPO is a public issue where the company offers its shares to investors through the stock exchange, allowing retail, HNI, and institutional participation.
What is the IPO price band of Anlon Healthcare Limited IPO?
The IPO price band of Anlon Healthcare Limited IPO is ₹₹91 per share, as mentioned in the issue details.
What is the minimum investment required for Anlon Healthcare Limited IPO?
The minimum investment in Anlon Healthcare Limited IPO is ₹14,924, based on the applicable lot size for retail investors.
What is the lot size of Anlon Healthcare Limited IPO?
The lot size of Anlon Healthcare Limited IPO is 164 shares per lot, and applications must be made in multiples of this lot size.
What are the opening and closing dates of Anlon Healthcare Limited IPO?
Anlon Healthcare Limited IPO opens on 26 Aug 2025 and closes on 29 Aug 2025, as per the announced schedule.
What is Anlon Healthcare Limited IPO subscription status?
Anlon Healthcare Limited IPO subscription status shows the level of demand across retail, HNI, and institutional investor categories during the issue period.
What is Anlon Healthcare Limited IPO GMP today?
Anlon Healthcare Limited IPO GMP (Grey Market Premium) today is around ₹TBA, reflecting current grey market activity before listing.
Is Anlon Healthcare Limited IPO GMP positive or negative?
Anlon Healthcare Limited IPO GMP is currently subject to change, based on prevailing grey market trends. GMP may change over time.
What does Anlon Healthcare Limited IPO GMP indicate for listing?
A positive Anlon Healthcare Limited IPO GMP may indicate market interest ahead of listing, while actual listing performance depends on subscription response and market conditions.
When is Anlon Healthcare Limited IPO listing date?
The expected listing date of Anlon Healthcare Limited IPO is 3 Sept 2025, subject to completion of the allotment process.
Where can I check Anlon Healthcare Limited IPO allotment status?
Anlon Healthcare Limited IPO allotment status can be checked online once the allotment process is completed using application or PAN details.
Can Anlon Healthcare Limited IPO subscription and GMP change before listing?
Yes, Anlon Healthcare Limited IPO subscription figures and GMP may change during the issue period and before listing based on market activity.

Anlon Healthcare Limited IPO Ratings & reviews

Community ratings and reviews — not financial advice.

No ratings yet — be the first to share your experience.

Loading ratings…
Follow the latest IPO & unlisted research on iOS and Android.